PURPOSE: To analyze the difference in anterior chamber depth (ACD) after uneventful cataract surgery between two hydrophobic acrylic single-piece intraocular lenses (IOLs) with different material properties. SETTING: Hanusch Hospital, Vienna, Austria. DESIGN: Single-center, bilateral randomized paired-eye controlled study. METHODS:Patients scheduled for bilateral cataract surgery were randomized to receive the Clareon IOL in one eye and the AcrySof IQ IOL (both Alcon Laboratories Inc.) in the contralateral eye. Preoperatively a slit lamp examination, optical biometry (IOLMaster 700, Carl Zeiss Meditec AG), refraction and visual acuity measurements were performed. ACD was assessed 1 hour and 1 week after surgery as well as with additional measurement of uncorrected (UDVA) and corrected distance visual acuity (CDVA) 6 months postoperatively. RESULTS:Eighty eyes of 40 patients were analyzed in this study. ACD at the 6-month follow-up was 3.94 ± 0.30 mm for the Clareon IOL and 3.91 ± 0.32 mm for the AcrySof IQ IOL (P=.08). Statistically significant differences in the ACD shift between both IOLs were detected between 1 week and 6 months (P=.04) and 1 hour to 6 months (P=.04). There were no significant differences between both IOLs in UDVA (P=.78), in CDVA (P=.59) and in spherical equivalent (SE, P=.39) at the 6-month visit. The mean absolute error between the measured and the aimed SE was not significant (P=.97). CONCLUSIONS: There was no clinically relevant difference in ACD between the Clareon IOL and the AcrySof IQ IOL in patients after uneventful cataract surgery. Both IOLs yielded good refraction and visual acuity outcomes.
RCT Entities:
PURPOSE: To analyze the difference in anterior chamber depth (ACD) after uneventful cataract surgery between two hydrophobic acrylic single-piece intraocular lenses (IOLs) with different material properties. SETTING: Hanusch Hospital, Vienna, Austria. DESIGN: Single-center, bilateral randomized paired-eye controlled study. METHODS:Patients scheduled for bilateral cataract surgery were randomized to receive the Clareon IOL in one eye and the AcrySof IQ IOL (both Alcon Laboratories Inc.) in the contralateral eye. Preoperatively a slit lamp examination, optical biometry (IOLMaster 700, Carl Zeiss Meditec AG), refraction and visual acuity measurements were performed. ACD was assessed 1 hour and 1 week after surgery as well as with additional measurement of uncorrected (UDVA) and corrected distance visual acuity (CDVA) 6 months postoperatively. RESULTS: Eighty eyes of 40 patients were analyzed in this study. ACD at the 6-month follow-up was 3.94 ± 0.30 mm for the Clareon IOL and 3.91 ± 0.32 mm for the AcrySof IQ IOL (P=.08). Statistically significant differences in the ACD shift between both IOLs were detected between 1 week and 6 months (P=.04) and 1 hour to 6 months (P=.04). There were no significant differences between both IOLs in UDVA (P=.78), in CDVA (P=.59) and in spherical equivalent (SE, P=.39) at the 6-month visit. The mean absolute error between the measured and the aimed SE was not significant (P=.97). CONCLUSIONS: There was no clinically relevant difference in ACD between the Clareon IOL and the AcrySof IQ IOL in patients after uneventful cataract surgery. Both IOLs yielded good refraction and visual acuity outcomes.